S1 Episode 3: What New Antipsychotic Drugs Are Available for Schizophrenia? What Drugs Are Under Development? And What Do They Potentially Offer?

S1 Episode 3: What New Antipsychotic Drugs Are Available for Schizophrenia? What Drugs Are Under Development? And What Do They Potentially Offer?

Drs John Kane and Jonathan M. Meyer discuss what new antipsychotic drugs are available for schizophrenia. What drugs are under development? And what do they potentially offer?

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969528). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

The Clozapine Handbook: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) New Edition https://www.amazon.com/Clozapine-Handbook-Handbooks-Essential-Psychopharmacology/dp/1108447465

The Clinical Use of Antipsychotic Plasma Levels: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) Kindle Edition https://www.amazon.com/Clinical-Antipsychotic-Plasma-Levels-Psychopharmacology-ebook-dp-B09B3VMM8N/dp/B09B3VMM8N

Clinical Use of Reserpine in Psychiatry: Comparison With Chlorpromazine https://nyaspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1749-6632.1955.tb42463.x

Arvid Carlsson https://www.nobelprize.org/prizes/medicine/2000/carlsson/facts/

Clozapine: Guidelines for Clinical Management https://pubmed.ncbi.nlm.nih.gov/2670914/

Clozapine: Medscape Drugs & Diseases https://reference.medscape.com/drug/clozaril-versacloz-clozapine-342972

Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-analysis https://www.psychiatrist.com/jcp/movement-disorder/tardive-dyskinesia-prevalence/

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia — A Randomized Clinical Trial https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2758022

Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities https://pubs.acs.org/doi/10.1021/acsptsci.2c00016

Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity https://jpet.aspetjournals.org/content/324/3/948.long

A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa1911772

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia https://clinicaltrials.gov/ct2/show/NCT04109950

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms https://clinicaltrials.gov/ct2/show/NCT03669640

Emerging Schizophrenia Drugs Target Negative Symptoms https://www.medscape.com/viewarticle/953336

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2008.06091591

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa2017015

Risperidone, 2 mg/day vs. 4 mg/day, in First-Episode, Acutely Psychotic Patients: Treatment Efficacy and Effects on Fine Motor Functioning https://www.psychiatrist.com/jcp/schizophrenia/risperidone-mgday-vs-mgday-episode-acutely-psychotic/

Jaksot(12)

S2 Episode 6: Is MDMA a Potential Treatment for Negative Symptoms of Schizophrenia? Exploring Stigma and Strategies to Alleviate Symptoms

S2 Episode 6: Is MDMA a Potential Treatment for Negative Symptoms of Schizophrenia? Exploring Stigma and Strategies to Alleviate Symptoms

Drs John M. Kane and Mitchell Arnovitz discuss assessment of patients for negative symptoms of schizophrenia and the potential of MDMA in alleviating these symptoms in supervised treatment settings. R...

20 Heinä 202322min

S2 Episode 5: First-Episode Schizophrenia: The Importance of Engaging and Educating Patients and Their Families in Treatment

S2 Episode 5: First-Episode Schizophrenia: The Importance of Engaging and Educating Patients and Their Families in Treatment

Drs John M. Kane and Delbert G. Robinson discuss psychoeducation, treatment options, and possible side effects of medication for patients experiencing their first episode of schizophrenia. Relevant di...

21 Kesä 202322min

S2 Episode 4: Common and Commonly Unrecognized: Clinical High-risk Syndrome, Psychosis, and Schizophrenia

S2 Episode 4: Common and Commonly Unrecognized: Clinical High-risk Syndrome, Psychosis, and Schizophrenia

Drs John M. Kane and Scott W. Woods discuss clinical high-risk syndrome and schizophrenia, including assessment methods, interventions, and risk indicators for future psychosis. Relevant disclosures c...

23 Touko 202318min

S2 Episode 3: Psychiatric Comorbidity in Schizophrenia: Assessing Patients and the Impact on Treatment Decisions and Outcomes

S2 Episode 3: Psychiatric Comorbidity in Schizophrenia: Assessing Patients and the Impact on Treatment Decisions and Outcomes

Drs John M. Kane and Christoph U. Correll discuss the importance of ongoing assessment of psychiatric comorbidities in patients with schizophrenia and its impact on outcomes and treatment decisions. R...

19 Huhti 202324min

S2 Episode 2: Long-Acting Injectables and Schizophrenia: Mitigating the Risk for Relapse and Rehospitalization

S2 Episode 2: Long-Acting Injectables and Schizophrenia: Mitigating the Risk for Relapse and Rehospitalization

Drs John M. Kane and Jose Rubio-Lorente discuss the value of long-acting injectable formulations in reducing the risk for relapse and rehospitalization for patients diagnosed with schizophrenia. Relev...

22 Maalis 202323min

S2 Episode 1: Treatment-Resistant Schizophrenia: Detection, Management, and the Importance of Early Initiation of Treatment

S2 Episode 1: Treatment-Resistant Schizophrenia: Detection, Management, and the Importance of Early Initiation of Treatment

Drs John M. Kane and Jonathan Meyer discuss treatment-resistant schizophrenia, how common it is, how to detect and manage it, and how delays in the initiation of treatment negatively affect patients. ...

22 Maalis 202325min

S1 Episode 6: Relapse in Schizophrenia: Why It Occurs, How Often It Occurs, and What We Can Do About It

S1 Episode 6: Relapse in Schizophrenia: Why It Occurs, How Often It Occurs, and What We Can Do About It

Drs John Kane and Jose Rubio-Lorente discuss relapse in schizophrenia — why it occurs, how often it occurs, and what we can do about it. Relevant disclosures can be found with the episode show notes o...

7 Joulu 202223min

S1 Episode 5: Neuroimaging in Schizophrenia: What Have We Learned?

S1 Episode 5: Neuroimaging in Schizophrenia: What Have We Learned?

Drs John Kane and Anil Malhotra discuss neuroimaging and connectivity between various regions of the brain in patients with schizophrenia and how it impacts the pathophysiology and treatment response....

9 Marras 202222min

Suosittua kategoriassa Tiede

rss-poliisin-mieli
rss-mita-tulisi-tietaa
utelias-mieli
tiedekulma-podcast
docemilia
radio-antro
filocast-filosofian-perusteet
rss-duodecim-lehti
rss-ylistys-elaimille
university-of-eastern-finland
vinkista-vihia
sotataidon-ytimessa
rss-ranskaa-raakana
rss-paanavauksia
rss-astetta-parempi-elama-podcast